Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells 977 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 977 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now directly owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Colleen Tupper also recently made the following trade(s):

• On Tuesday, March 11th, Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45.
• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00.

Collegium Pharmaceutical Stock Performance

Collegium Pharmaceutical stock opened at $29.93 on Friday. The stock has a market cap of $942.38 million, a price-to-earnings ratio of 12.90 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a 50 day simple moving average of $30.75 and a 200-day simple moving average of $32.77. Collegium Pharmaceutical, Inc. has a 1-year low of $27.28 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on COLL. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective on the stock in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the business. New Age Alpha Advisors LLC purchased a new position in Collegium Pharmaceutical during the fourth quarter worth about $40,000. TD Private Client Wealth LLC lifted its holdings in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after acquiring an additional 483 shares during the last quarter. KBC Group NV lifted its holdings in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares during the last quarter. Virtus Fund Advisers LLC boosted its position in shares of Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 565 shares during the period. Finally, Nisa Investment Advisors LLC increased its holdings in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.